US Bancorp
LCTX icon

US Bancorp’s Lineage Cell Therapeutics LCTX Stock Holding History

US Bancorp’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9
Closed – – 4138
2021
Q2 		$0 Buy
+9
New +$23 ﹤0.01% 4042
2020
Q2 		– Sell
-44
Closed – – 3809
2020
Q1 		$0 Hold
44
– – ﹤0.01% 3738
2019
Q4 		$0 Hold
44
– – ﹤0.01% 3695
2019
Q3 		$0 Sell
44
-443
-91% -$459 ﹤0.01% 3631
2019
Q2 		$1K Hold
487
– – ﹤0.01% 3554
2019
Q1 		$1K Buy
+487
New +$606 ﹤0.01% 3497

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

US Bancorp's LCTX Position: Q3 2021 in Review

US Bancorp sold out of Lineage Cell Therapeutics (LCTX) in Q3 2021, closing a stake of 9 shares.

US Bancorp first reported a position in LCTX in Q1 2019 and held it in 6 quarters. The position peaked at $1K in Q2 2019. 115 funds tracked by Wall St. Rank hold LCTX as of Q3 2021.

  • US Bancorp reported no remaining Lineage Cell Therapeutics position as of Q3 2021 after selling out during the quarter.
  • US Bancorp sold 9 Lineage Cell Therapeutics shares in Q3 2021.
  • US Bancorp first reported a position in Lineage Cell Therapeutics in Q1 2019 and held it in 6 quarters.
  • US Bancorp's Lineage Cell Therapeutics position peaked at $1K in Q2 2019.
  • 115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2021.

Based on US Bancorp's 13F filing for Q3 2021, filed 10 Nov 2021.